News & events
Press Releases
On the 28th March 2022, OncoArendi changed its name to Molecure
Dr Piotr Iwanowski appointed as Chief Medical Officer and Board Member of Molecure
1 August 2024
Avicenna Biosciences and Molecure S.A. Sign Strategic Research Collaboration Agreement to Accelerate Discovery and Development of Small Molecule Drugs
31 July 2024
Molecure has confirmed the in vitro activity of another molecule binding to a new mRNA target within the mRNA discovery platform
12 June 2024
Molecure receives approval to initiate a Phase II clinical trial (KITE) for OATD-01 for the treatment of pulmonary sarcoidosis in selected countries of the European Union and Norway
21 May 2024
Molecure has published its financial report for the first quarter of 2024. The company is progressing, as anticipated, the next steps in the development of its clinical and pre-clinical programmes
17 May 2024
Molecure has published its financial report for 2023 – the company has significantly accelerated the development of its clinical and pre-clinical programmes and plans to make strong progress in research in 2024 and 2025
29 March 2024
Events & Presentations
EFMC – International Symposium on Medicinal Chemistry – Ljubljana 02-06.09.2018
17 September 2018
54th International Conference on Medicinal Chemistry, Strasbourg, France – July 4-6, 2018.
17 July 2018
AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 26 – 30, 2017
1 October 2017